INBX: Tinanggap ng FDA ang BLA para sa ozekibart; Itinakda ang PDUFA sa Abril 14, 2027

Tinanggap ng FDA ang paghahain ng BLA para sa ozekibart (INBRX-109) sa unresectable o metastatic conventional chondrosarcoma nang walang natukoy na isyu sa pagsusuri ng paghahain. Itinalaga ang PDUFA goal date na Abril 14, 2027, na nagtatatag ng regulatory timeline para sa posibleng pag-apruba.

Mahahalagang fact

Na-file: Hun 15, 2026, 08:06 PM
Kaganapan: Tinanggap ang aplikasyon
Direksyon: Positibo
Kumpanya: INBXInhibrx
Asset: ozekibart
Pinagmulan: SEC 8-K
Kumpiyansa: May source
Kalendaryo: Desisyon ng FDA (PDUFA) · Abr 14, 2027 · Positibo

Sipi mula sa source

inhibrx-20260615 FALSE 0002007919 0002007919 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2026 INHIBRX BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-42031 99-0613523 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 11025 N. Torrey Pines Road , Suite 140 La Jolla , CA 92037 (Address of Principal Executive Offices and Zip Code) Registrant’s telephone number, including area code: ( 858 ) 795-4220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the

SEC 8-K